Biomarker & Intervention Discovery
Gastroparesis
Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.
US DALYs1.55MWHO GHE 2021 · all ages
Global DALYs17.03MWHO GHE 2021 · worldwide
US mortality53.1K deaths/yrWHO GHE 2021
Global mortality404.6K deaths/yrWHO GHE 2021 · worldwide
Spontaneous remissionIdiopathic gastroparesis: spontaneous resolution in ~30-40% at 5 years (NIDDK natural history study); diabetic…
Best-intervention remissionDietary modification + glycaemic optimisation: 50-60% improvement in symptoms; metoclopramide: 30-40% short-term…
Gap sizeLarge — gastric electrical stimulation and pyloromyotomy are underused; metoclopramide misuse is the dominant…
Primary barrierpractice/access
Full remission profile →
Remission & chronicity
Spontaneous remission
Idiopathic gastroparesis: spontaneous resolution in ~30-40% at 5 years (NIDDK natural history study); diabetic gastroparesis: rarely remits, correlated with glycaemic control; postsurgical: highly variable
Best-intervention remission
Dietary modification + glycaemic optimisation: 50-60% improvement in symptoms; metoclopramide: 30-40% short-term symptom improvement (limited by side effects); gastric electrical stimulation (Enterra Therapy): 50-60% significant symptom improvement at 3-5 years in refractory patients; pyloric procedures (G-POEM): 75-80% short-term improvement
Gap size
Large — gastric electrical stimulation and pyloromyotomy are underused; metoclopramide misuse is the dominant pharmacotherapy problem
Primary barrier
practice/access
Metoclopramide (the only FDA-approved drug for gastroparesis since 1979) carries a black box warning for tardive dyskinesia with >12 weeks use; yet many patients are maintained long-term; gastric electrical stimulation (GES) is underutilised and restricted to few centres; domperidone (off-label, superior safety) inaccessible in US except via FDA expanded access
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC.
Agents ranked: ● Clinical >
● Mechanistic >
● Correlative.
Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm
Clinical Trials
Recruiting and recently completed trials from ClinicalTrials.gov.
Data retrieved 2026-07-06.
No recent clinical trials found on ClinicalTrials.gov for this condition.
Agents Found By Disease-Level Search
Searched directly from “Gastroparesis” via ClinicalTrials.gov interventions and Open Targets'
disease→drug data — independent of the 0-gene target panel above.
This surfaces agents whose mechanism doesn't route through a curated gene (combination
therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."